ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
Clinical trial NCT07538401 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07538401
- Sponsor
- University Health Network, Toronto
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-25
- Primary completion
- 2028-04-25
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.